Tellus Therapeutics Announces $35 Million Series A Financing
Summary
The capital will be used to continue important preclinical work conducted through the seed investment with the Xontogeny development team and to advance TT-20, the companys lead candidate for the treatment of white matter brain injury in preterm infants, as well as the companys pipeline programs.We are pleased to see our partnership with Xontogeny thriving and joined by Perceptive Advisors PXV Fund, said Jason Kralic, Tellus co-founder and Chief Executive Officer. Tellus is navigating a complex development pathway for neonate-first innovations, and we believe that they are positioned to become a leader in the space, said Chris Garabedian, Portfolio Manager of PXV Funds and Chief Executive Officer of Xontogeny. Tellus Therapeutics is led by Jason Kralic, Eric Benner (Co-Founder and acting Chief Scientific Officer) and Austin Schwartz (Vice President of Operations). Dr. Benners work identified compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and repair WMI in animal models of perinatal brain injury. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
